Literature DB >> 22441393

Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Sergei Spitsin1, Nancy B Tustin, Eric Riedel, Richard Tustin, Jennifer B Murray, Lauren M Peck, Mohammad Khan, Joseph Quinn, Steven D Douglas.   

Abstract

This study investigates the short-term effects of highly active antiretroviral therapy (HAART) on programmed death 1 receptor (PD-1) expression and lymphocyte function. We compared lymphocytes from human immunodeficiency virus (HIV)-infected adults prior to the initiation of HAART with lymphocytes from the same subjects following 2 months of treatment. Short-term HAART resulted in a moderate increase in the expression of PD-1 on both CD4(+) and CD8(+) T cells; yet, there was still a significant reduction in viral load and recovery of CD4(+) T cells. After 2 months of HAART, lymphocytes from the subjects had a reduction in lymphoproliferative responses to phytohemagglutinin (PHA) and an increased response to the Candida recall antigen and the HIV antigen p24 compared to pretreatment lymphocytes. PHA-stimulated peripheral blood mononuclear cells (PBMCs) from samples obtained 2 months after HAART produced higher levels of Th-1 cytokines (gamma interferon [IFN-γ] and tumor necrosis factor alpha[TNF-α]) than the levels observed for samples taken before treatment was initiated. There were no significant changes in the proinflammatory cytokine interleukin-2 (IL-2) or Th-2 cytokines (IL-4, IL-5, and IL-10) in the corresponding samples. Ex vivo PD-1 blockade significantly augmented PHA-induced lymphoproliferation as well as the levels of Th-1 cytokines and to a lesser extent the levels of Th-2 cytokines in PBMC cultures. The ability to downregulate PD-1 expression may be important in enhancing immune recovery in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441393      PMCID: PMC3346323          DOI: 10.1128/CVI.00093-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  Immune function and phenotype before and after highly active antiretroviral therapy.

Authors:  S R Søndergaard; H Aladdin; H Ullum; J Gerstoft; P Skinhøj; B K Pedersen
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

3.  Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.

Authors:  Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2010-03-07       Impact factor: 53.440

4.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

5.  Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure.

Authors:  M Peruzzi; C Azzari; L Galli; A Vierucci; M De Martino
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B.

Authors:  Liangen Chen; Zheng Zhang; Weiwei Chen; Zhidong Zhang; Yonggang Li; Ming Shi; Jiyuan Zhang; Lieping Chen; Shengdian Wang; Fu-Sheng Wang
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

7.  CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients.

Authors:  Junyan Han; Beibei Wang; Ning Han; Yan Zhao; Chuan Song; Xin Feng; Yu Mao; Fujie Zhang; Hongxin Zhao; Hui Zeng
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

8.  PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples.

Authors:  Malin Holm; Frank Olav Pettersen; Dag Kvale
Journal:  Curr HIV Res       Date:  2008-01       Impact factor: 1.581

9.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

Authors:  Damalie Nakanjako; Agnes Kiragga; Fowzia Ibrahim; Barbara Castelnuovo; Moses R Kamya; Philippa J Easterbrook
Journal:  AIDS Res Ther       Date:  2008-10-28       Impact factor: 2.250

View more
  6 in total

1.  Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Isaac Ssinabulya; Agnes Kiragga; Andrew Kambugu; Joseph Olobo; Moses Joloba; Moses R Kamya; Harriet Mayanja-Kizza; Damalie Nakanjako
Journal:  Immunol Lett       Date:  2014-09-26       Impact factor: 3.685

2.  The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.

Authors:  Jeffrey M Greeson; David R Gettes; Sergei Spitsin; Benoit Dubé; Tami D Benton; Kevin G Lynch; Steven D Douglas; Dwight L Evans
Journal:  Biol Psychiatry       Date:  2015-11-10       Impact factor: 13.382

3.  A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection.

Authors:  Yusuke Okuma; Junko Tanuma; Hiroshi Kamiryo; Yuki Kojima; Mihoko Yotsumoto; Atsushi Ajisawa; Tomoko Uehira; Hirokazu Nagai; Yuichiro Takeda; Yasuhiro Setoguchi; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-24       Impact factor: 4.553

4.  Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Authors:  Florin Tuluc; Sergei Spitsin; Nancy B Tustin; Jennifer B Murray; Richard Tustin; Laura A Schankel; Andrew Wiznia; Sharon Nachman; Steven D Douglas
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-18       Impact factor: 2.205

5.  Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease.

Authors:  Leslie R Cockerham; Vivek Jain; Elizabeth Sinclair; David V Glidden; Wendy Hartogenesis; Hiroyu Hatano; Peter W Hunt; Jeffrey N Martin; Christopher D Pilcher; Rafick Sekaly; Joseph M McCune; Frederick M Hecht; Steven G Deeks
Journal:  AIDS       Date:  2014-07-31       Impact factor: 4.177

6.  Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy.

Authors:  Truong Tam Nguyen; Reihani Niloofar; Pierre-Alain Rubbo; Kuster Nils; Karine Bollore; Jacques Ducos; Georges-Philippe Pageaux; Jacques Reynes; Philippe Van de Perre; Edouard Tuaillon
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-01-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.